)--GlycoMimetics, Inc. (GMI) today announced that the company and its collaborators highlighted its novel glycomimetic drug candidate, E-selectin antagonist GMI-1271, during an oral presentation and poster session at the 2013 American Society of Hematology (ASH) Annual Meeting and Exposition. GMI-1271 is currently in preclinical studies for blood cancers and other cancers that are associated with elevated risk of metastasis and thrombosis.
Help employers find you! Check out all the jobs and post your resume.
